MarketBeat on MSN7h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
stockhead19h
Health Check: The urge to merge is spurring a global biotech recovery
Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...